Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor

Biomaterials

Volumn 94, Issue , 2016, Pages 1-8

  Chung, Seung Woo ^a   Choi, Jeong uk ^a   Lee, Beom Seok ^b,c   Byun, Julia ^d   Jeon, Ok Cheol ^e   Kim, Seong Who ^b   Kim, In San ^c   Kim, Sang Yoon ^b   Byun, Youngro ^a  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d FRANKLIN AND MARSHALL COLLEGE   (United States)

^e Pharosgen Co   (South Korea)

Author keywords

Albumin; Apoptosis; Caspase; Drug delivery; Prodrug; Radiotherapy

Indexed keywords

BINDING ENERGY; CELL DEATH; DRUG DELIVERY; RADIOTHERAPY;

ALBUMIN; CASPASES; INTRAVENOUS ADMINISTRATION; PRODRUGS; RADIATION-INDUCED APOPTOSIS; SYSTEMIC TOXICITIES; THERAPEUTIC EFFECTS; THERAPEUTIC EFFICACY;

TUMORS;

ALBUMIN; CASPASE 3; DOXORUBICIN; HUMAN SERUM ALBUMIN; PRODRUG; ALBUMINOID; HEXANOIC ACID; HEXANOIC ACID DERIVATIVE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RAT; TREATMENT RESPONSE; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ALBUMINS; ANIMALS; CAPROATES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HUMANS; MALE; MICE; NEOPLASMS; PEPTIDES; PRODRUGS; UP-REGULATION;

EID: 84962812152     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.043     Document Type: Article

References (25)

1. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
2. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 2011, 153:198-205.
3. Bae Y.H. Drug targeting and tumor heterogeneity. J. Control. Release 2009, 133:2-3.
4. Lee B.S., Cho Y.W., Kim G.C., Lee do H., Kim C.J., Kil H.S., et al. Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy. J. Natl. Cancer Inst. 2015, 107.
5. Chung S.W., Lee B.S., Choi J., Kim S.W., Kim I.S., Kim S.Y., et al. Optimization of a stable linker involved DEVD peptide-doxorubicin conjugate that is activated upon radiation-induced caspase-3-mediated apoptosis. J. Med. Chem. 2015, 58:6435-6447.
6. Bucci B., Misiti S., Cannizzaro A., Marchese R., Raza G.H., Miceli R., et al. Fractionated ionizing radiation exposure induces apoptosis through caspase-3 activation and reactive oxygen species generation. Anticancer Res. 2006, 26:4549-4557.
7. Huang Q., Li F., Liu X., Li W., Shi W., Liu F.F., et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 2011, 17:860-866.
8. Kratz F., Beyer U. Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv. 1998, 5:281-299.
9. Kratz F., Muller-Driver R., Hofmann I., Drevs J., Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 2000, 43:1253-1256.
10. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., Lazar P., et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 2002, 45:5523-5533.
11. Chung D.E., Kratz F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 2006, 16:5157-5163.
12. Schmid B., Chung D.E., Warnecke A., Fichtner I., Kratz F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug. Chem. 2007, 18:702-716.
13. Graeser R., Chung D.E., Esser N., Moor S., Schachtele C., Unger C., et al. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int. J. Cancer 2008, 122:1145-1154.
14. Peters T. Serum albumin. Adv. Protein Chem. 1985, 37:161-245.
15. Dennis M.S., Zhang M., Meng Y.G., Kadkhodayan M., Kirchhofer D., Combs D., et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 2002, 277:35035-35043.
16. Chaudhury C., Mehnaz S., Robinson J.M., Hayton W.L., Pearl D.K., Roopenian D.C., et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 2003, 197:315-322.
17. Stehle G., Sinn H., Wunder A., Schrenk H.H., Stewart J.C., Hartung G., et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol. 1997, 26:77-100.
18. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
19. Desai N., Trieu V., Damascelli B., Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2009, 2:59-64.
20. Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs 2007, 16:855-866.
21. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 1997, 272:17907-17911.
22. Werle M., Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006, 30:351-367.
23. Assumpção J.U., Campos M.L., Ferraz Nogueira Filho M.A., Pestana K.C., Baldan H.M., Formariz Pilon T.P., et al. Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin. J. Pharm. Sci. 2013, 102:289-296.
24. Sell S. The catabolism of alpha1-fetoprotein and albumin in rats bearing Morris hepatoma 7777. Cancer Res. 1974, 34:1608-1611.
25. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines,. Cancer 2005, 104:1129-1137.